Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOG0507-A)

Gastric Cancer

Volumn 17, Issue 3, 2014, Pages 514-521

  Kurokawa, Yukinori ^a   Shibata, Taro ^b   Sasako, Mitsuru ^c   Sano, Takeshi ^d   Tsuburaya, Akira ^e   Iwasaki, Yoshiaki ^f   Fukuda, Haruhiko ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d CANCER INSTITUTE HOSPITAL   (Japan)

^e KANAGAWA CANCER CENTER   (Japan)

^f TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

JCGC; JCOG; RECIST

Indexed keywords

CISPLATIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; DRUG COMBINATION; OTERACIL; S 1 (COMBINATION); TEGAFUR;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GASTRECTOMY; GASTROSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INSTRUMENT VALIDATION; INTERMETHOD COMPARISON; JAPANESE CLASSIFICATION OF GASTRIC CARCINOMA; LINITIS PLASTICA; LONG TERM SURVIVAL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SHORT TERM SURVIVAL; STOMACH CANCER; STOMACH ULCER; TUMOR INVASION; ADJUVANT THERAPY; CLASSIFICATION; CLINICAL TRIAL; DRUG COMBINATION; METASTASIS; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROCEDURES; PROPORTIONAL HAZARDS MODEL; STOMACH NEOPLASMS; SURVIVAL RATE; TIME; TREATMENT OUTCOME; VALIDATION STUDY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OXONIC ACID; PROPORTIONAL HAZARDS MODELS; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84902386468     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-013-0294-2     Document Type: Article

References (19)

1. GLOBOCAN. http://globocan.iarc.fr/ (2008).
2. Sasako M, Sano T, Yamamoto S, Sairenji M, Arai K, Kinoshita T, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol. 2006;7:644-51. (Pubitemid 44123569)
3. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359:453-62.
4. Nashimoto A, Akazawa K, Isobe Y, Miyashiro I, Katai H, Kodera Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16:1-27.
5. Kinoshita T, Sasako M, Sano T, Katai H, Furukawa H, Tsuburaya A, et al. Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002). Gastric Cancer. 2009;12:37-42.
6. Keighley MR, Moore J, Roginski C, Powell J, Thompson H. Incidence and prognosis of N4 node involvement in gastric cancer. Br J Surg. 1984;71:863-6. (Pubitemid 15212011)
7. Iwasaki Y, Sasako M, Yamamoto S, Nakamura K, Sano T, Katai H, et al. Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). J Surg Oncol 2013;107(7):741-745
8. Yoshikawa T, Nakamura K, Tsuburaya A, Sano T, Mizusawa J, Katai H, et al. A phase II study of preoperative chemotherapy with S-1 (S) and cisplatin (P) followed by D3 gastrectomy for gastric cancer (GC) with extensive lymph node metastasis (ELM): survival results of JCOG0405. J Clin Oncol 2011;29(suppl 4): abstr 70
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
10. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 2nd English edition. Response assessment of chemotherapy and radiotherapy for gastric carcinoma: clinical criteria. Gastric Cancer. 2001;4:1-8.
11. Kurokawa Y, Shibata T, Ando N, Seki S, Mukaida H, Fukuda H. Which is the optimal response criteria for evaluating preoperative treatment in esophageal cancer: RECIST or histology? Ann Surg Oncol. 2013;20:3009-14.
12. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 3rd English edition. Gastric Cancer. 2011;14:101-12.
13. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
14. Becker K, Fumagalli U, Mueller JD, Fink U, Siewert JR, Hofler H. Neoadjuvant chemotherapy for patients with locally advanced gastric carcinoma: effect on tumor cell microinvolvement of regional lymph nodes. Cancer (Phila). 1999;85:1484-9. (Pubitemid 29152819)
15. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer (Phila). 2003;98:1521-30. (Pubitemid 37151509)
16. Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004;22:2774-80. (Pubitemid 41079894)
17. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 2005;23:1237-44. (Pubitemid 46202281)
18. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215-21.
19. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28:1547-53.